Prospective Registry Study and Clinical Observation of Children With Crohn's Disease
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- To evaluate the clinical manifestations, treatment options, and clinical outcomes of Crohn's disease in children in real-world Settings
研究概览
简要总结
To evaluate the clinical manifestations, treatment options, and improved clinical outcomeof children with Crohn's disease in real-world Settings: (1) analysis of clinical manifestations; (2) probability of using the same treatment options; (3) Clinical outcome;
详细描述
This study will aim to enroll approximately 100 patients with Crohn Disease (CD). All patients who have CD will be evaluated at the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Patients who are eligible for the study will be identified during these regularly scheduled clinic visits. Patients and guardians who express interest will be set up for a meeting with a clinical research coordinator who will go over the study in detail and will obtain informed consent. Before the therapeutic intervention,stool samples will be checked for ova and parasites, C. difficile toxin and fecal calprotectin (FCP). Serum tests will include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Anti-nuclear antibodies (ANA), complete blood cell count, HIV, screening for Hepatitis A, B, C (hep A IgM, hep B surface antigen and antibody, Hep C antibody), and creatinine. Fecal tests included 16S rDNA flora detection and metabolite detection. Patients with CD will undergo colonoscopy, which is considered part of standard of care for patients with ongoing inflammation and is not considered a study procedure.
Dynamic monitoring follow-up up to 102 weeks, dynamic assessment of relevant indicators, such as ESR, CRP, FCP and endoscopy, etc. This study is an observational study, without intervention in the treatment of patients. Patients will accept the treatment plan formulated by the attending physician. Treatment options include: enteral nutrition (EEN/ PEN, reason, route of administration, dose, course of treatment); glucocorticoids (reason, route of administration, dose, course of treatment); immunosuppressants (reason, route of administration, dose, course of treatment); biologics (including domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd)) (dose, duration, effectiveness, safety, and economy); fecal microbiota transplantation (cause, transplantation routes, capsule fecal transplants, dose, course of treatment); the medical costs and resource consumption of the treatment of Crohn's disease in children. The difference of efficacy of the above treatment schemes was recorded, the treatment outcome was compared, and the transformation of treatment schemes was discussed. Researchers and patients will truthfully register the corresponding data generated by clinical practice from the doctors and patients respectively, collect the laboratory examination and evaluation data of doctors during the visit, and combine the hospital visit and electronic information system. Statistical analysis was performed after follow-up.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 1 Month 至 16 Years(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children under 17 years old;
- •Children with a definite diagnosis of Crohn's disease;
- •Patients and their guardians must sign informed consent;
排除标准
- •Other conditions deemed inappropriate by the doctor to participate in the study;
研究组 & 干预措施
Glucocorticoid group
Glucocorticoid therapy
干预措施: biological agents (Drug)
Immunosuppressive group
Immunosuppressive therapy
干预措施: biological agents (Drug)
Glucocorticoid group
Glucocorticoid therapy
干预措施: fecal microbiota transplantation (Other)
Immunosuppressive group
Immunosuppressive therapy
干预措施: enteral nutrition (Drug)
enteral nutrition group
enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition
干预措施: Immunotherapy (Drug)
enteral nutrition group
enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition
干预措施: biological agents (Drug)
enteral nutrition group
enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition
干预措施: Glucocorticoids (Drug)
enteral nutrition group
enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition
干预措施: fecal microbiota transplantation (Other)
Glucocorticoid group
Glucocorticoid therapy
干预措施: enteral nutrition (Drug)
Immunosuppressive group
Immunosuppressive therapy
干预措施: fecal microbiota transplantation (Other)
Fecal Microbiota Transplantation group
Fecal Microbiota Transplantation therapy
干预措施: enteral nutrition (Drug)
Fecal Microbiota Transplantation group
Fecal Microbiota Transplantation therapy
干预措施: Immunotherapy (Drug)
Fecal Microbiota Transplantation group
Fecal Microbiota Transplantation therapy
干预措施: biological agents (Drug)
Fecal Microbiota Transplantation group
Fecal Microbiota Transplantation therapy
干预措施: Glucocorticoids (Drug)
Biologics group
Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).
干预措施: enteral nutrition (Drug)
Biologics group
Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).
干预措施: Immunotherapy (Drug)
Biologics group
Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).
干预措施: Glucocorticoids (Drug)
Biologics group
Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).
干预措施: fecal microbiota transplantation (Other)
结局指标
主要结局
To evaluate the clinical manifestations, treatment options, and clinical outcomes of Crohn's disease in children in real-world Settings
时间窗: 14 weeks
14 weeks clinical response rate.
次要结局
- Clinical remission of different treatment regimens(14 and 54 weeks)
- Clinical response of different treatment regimens(54 weeks)
- Endoscopic response of different treatment regimens(14 and 54 weeks)
- Mucosal healing of different treatment regimens(14 and 54 weeks)
- C-reactive protein of different treatment regimens(14 and 54 weeks)
- Erythrocyte sedimentation rate of different treatment regimens(14 and 54 weeks)
- Fecal calprotectin of different treatment regimens(14 and 54 weeks)
- Intestinal flora of different treatment regimens(14 and 54 weeks)
研究者
Biao Zou
Attending physician, pediatric department
Tongji Hospital
